Cardionovum® is present in the Archives of Internal Medicine Research (ISSN: 2688-5654) in the article entitled “Drug Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistula: A New Standard-of-Care in the Horizon?”.
In this recent article, Dr. Lichtenberg unveils the role of DCBs in Vascular Access Management, and an entire chapter is devoted to our Aperto® OTW drug coated balloon with an extensive overview of its main technical features and clinical results.
The Archives of Internal Medicine Research (ISSN: 2688-5654) is an open access peer-reviewed journal providing innovative and clinically relevant research platform for physicians, practitioners, pathologists, pharmacologist and students in general internal medicine and internal medicine subspecialties with an Impact Factor 3.6.
We are glad to announce Cardionovum®'s prestigious recognition as one of the Top 10 Cardiovascular Solutions Companies in Europe for 2023 by MedTech Outlook.
This acknowledgment reflects our unwavering commitment to innovation and excellence within the field of cardiovascular solutions.
Being included in this list is a proof to our Team's dedication and the impact of our pioneering technologies.
In addition, we are honored to be present in the November edition of MedTech Outlook magazine, providing an in-depth article that delves into our contributions in driving innovation to improve patients' lives.
Cardionovum® is present in the Vascular News’s November edition with an article in which Prof. Tozzi (Varese, Italy) shares the clinical outcomes of the Aperto 600 Study, in which more than 600 Aperto® DCBs have been used in ArteriousVenous Fistula (AVF) and ArteriousVenous Graft (AVG), including a large number of Central Vein Stenosis (CVS).
Cardionovum® announces that the XLIMIT Trial results, featuring the XLIMUS® DES, have been published online in the Frontiers in Cardiovascular Medicine journal with the article entitled “A randomized control trial to assess optical coherence tomography parameters of the Xlimus drug-eluting stent: the XLIMIT trial”.
XLIMIT is a non-inferiority, prospective, multicenter, randomized, controlled trial in which a total of 177 patients were enrolled and randomized in two groups in a 2:1 ratio (2 XLIMUS®:1 Synergy™).
The primary endpoint of this study has been defined as the in-stent neointimal volume weighted by the sum of the lengths of implanted stent (ISNV), and the in-stent percent neointimal volume obstruction (%VO) were evaluated at 6-9 months by means of Optical Coherence Tomography (OCT).
Cardionovum® announces that the HYPER Study results, featuring the innovative RESTORE® DEB, have been published online in the Minerva Cardiology and Angiology journal, with the article entitled "Procedural and one-year outcomes following drug-eluting stent and drug-coated balloon combination for the treatment of de novo diffuse coronary artery disease: the HYPER Study”.
The HYPER is a prospective, multicenter study including patients affected by de novo diffuse CAD treated with a hybrid approach from April 2019 to December 2020, having as primary endpoint the evaluation of the 1-year device-oriented composite endpoint (DoCE, cardiac death, target vessel myocardial infarction and ischemia-driven target lesion revascularization [ID-TLR]).
Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2023 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.
In this video interview, Dott. Ielasi summarizes the benefits of RESTORE® paclitaxel eluting balloon and comments the results of the Hyper study at 2 years, putting a focus on the encouraging results of the combined use of modern DES and RESTORE® DEB in the context of de novo diffuse CAD: in detail, results showed a 2-year clinical follow-up available for the vast majority of the patients enrolled (n=105/106, 99%) and a low incidence of Device oriented Composite Endpoint (DoCE) equal to 4.6% at 24 months.
In conclusion, even if larger and more robust data from RCTs (vs. full metal jacket PCIs) are needed to confirm the findings, the HYPER study reports very encouraging results in terms of safety and efficacy of the hybrid approach in the treatment of diffuse CAD.